Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 32,895 |
|
|||||
| News | - | ||||||
| Day High | 0.864 | Low High |
|||||
| Day Low | 0.8201 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Viracta Therapeutics Inc | VIRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.0107 | 1.28% | 0.847 | 17:51:32 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.85 | 0.8201 | 0.864 | 0.847 | 0.8363 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 183 | 32,895 | $ 0.8364177 | $ 27,514 | - | 0.43 - 2.38 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:39:56 | 1 | $ 0.84 | USD |
Viracta Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 32.6M | 39.27M | - | 0 | -51.06M | -1.30 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Viracta Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VIRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.91 | 0.99 | 0.76 | 0.8658434 | 56,959 | -0.063 | -6.92% |
| 1 Month | 1.05 | 1.31 | 0.67 | 0.9750888 | 155,842 | -0.203 | -19.33% |
| 3 Months | 0.55 | 1.31 | 0.54 | 0.8883851 | 119,224 | 0.297 | 54.00% |
| 6 Months | 0.72 | 1.31 | 0.43 | 0.6842148 | 142,217 | 0.127 | 17.64% |
| 1 Year | 1.30 | 2.38 | 0.43 | 1.13 | 154,853 | -0.453 | -34.85% |
| 3 Years | 9.07 | 13.08 | 0.43 | 4.30 | 188,426 | -8.22 | -90.66% |
| 5 Years | 16.76 | 18.24 | 0.43 | 4.86 | 197,889 | -15.91 | -94.95% |
Viracta Therapeutics Description
| Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. |
